Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes.
- 1Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- 2Department of Dermatology, King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
- 3Department of Dermatology, Riyadh First Health Cluster, King Saud Medical City, Riyadh, Saudi Arabia.
Abstract
Risankizumab (anti-IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. To evaluate long-term effectiveness, safety, and treatment patterns-including extended-interval dosing-of Risankizumab in a real-world tertiary center. Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. We included 144 patients (mean age 39.3±14.9 years; 55.6% male; mean BMI 29.0±6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→0.34, BSA 9.81%→0.26%, DLQI 7.64→0.68, NAPSI 9.56→2.94 (all p<0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4-6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months' mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.
Related
- Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.
- Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience.
- Efficacy and Safety of 5% Topical Caffeine Added to 0.025% Fluocinolone Acetonide Cream for Plaque Psoriasis: A Randomized Controlled Trial.
- Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.
- Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives
BibTeX
@article{alkofide2026risankizumab,
title = {{Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes.}},
author = {Maha Alkofide and Abdulaziz Madani and Sarah Alsukait and Hend Alotaibi and Huda Salim Almaqbali and Naif Ahmed Alshehri and Maee Barakeh and Bandar Ahmed Alharbi and Khalid Nabil Nagshabandi},
journal = {Clinical, cosmetic and investigational dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s624904},
url = {https://europepmc.org/article/MED/42953760},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes.
AU - Maha Alkofide
AU - Abdulaziz Madani
AU - Sarah Alsukait
AU - Hend Alotaibi
AU - Huda Salim Almaqbali
AU - Naif Ahmed Alshehri
AU - Maee Barakeh
AU - Bandar Ahmed Alharbi
AU - Khalid Nabil Nagshabandi
PY - 2026
DA - 2026/10/24
JO - Clinical, cosmetic and investigational dermatology
DO - 10.2147/ccid.s624904
UR - https://europepmc.org/article/MED/42953760
AB - Risankizumab (anti-IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. To evaluate long-term effectiveness, safety, and treatment patterns-including extended-interval dosing-of Risankizumab in a real-world tertiary center. Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. We included 144 patients (mean age 39.3±14.9 years; 55.6% male; mean BMI 29.0±6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→0.34, BSA 9.81%→0.26%, DLQI 7.64→0.68, NAPSI 9.56→2.94 (all p<0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4-6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months' mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.
SN - 1178-7015
ER -